Market Cap 14.25B
Revenue (ttm) 2.36B
Net Income (ttm) 341.30M
EPS (ttm) N/A
PE Ratio 41.85
Forward PE 31.52
Profit Margin 14.49%
Debt to Equity Ratio 0.00
Volume 636,100
Avg Vol 781,528
Day's Range N/A - N/A
Shares Out 99.18M
Stochastic %K 93%
Beta 0.21
Analysts Strong Sell
Price Target $170.08

Company Profile

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat cong...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 858 617 7600
Address:
12780 El Camino Real, San Diego, United States
Doozio
Doozio Oct. 25 at 2:48 PM
$NBIX so this week on eps da huckleberries go thru da $$$ because 🐒🍌🧠⏰♾️
0 · Reply
CDMO
CDMO Oct. 23 at 8:33 PM
$NBIX nice runup into earnings
0 · Reply
IN0V8
IN0V8 Oct. 23 at 7:48 PM
$NBIX Bought at $19
1 · Reply
stoxx0007
stoxx0007 Oct. 22 at 1:40 PM
$NBIX 💪
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 21 at 4:45 PM
Enter: $NBIX NOV 21 2025 $145 CALLS Buy in Price: $4.93 - $5.18 Take Profit: $10.01 Stop Bleeding: $4.34 ROI Potential: 103% Exit Within: 3 Weeks https://moneygroup.us/alerts
1 · Reply
notreload_ai
notreload_ai Oct. 21 at 1:09 PM
Citi has a Buy rating and $175 price target for $NBIX , believing its pipeline success overshadows INGREZZA's competitive concerns and maintains market share.
0 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 10:54 AM
Citigroup updates rating for Neurocrine Biosciences ( $NBIX ) to Buy, target set at 175.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 20 at 5:30 PM
Enter: $NBIX NOV 21 2025 $145 CALLS Buy in Price: $4.93 - $5.80 Take Profit: $7.15 Stop Bleeding: $4.34 ROI Potential: 45% Exit Within: 2 Weeks https://moneygroup.us/alerts
0 · Reply
JarvisFlow
JarvisFlow Oct. 20 at 3:41 PM
Morgan Stanley updates rating for Neurocrine Biosciences ( $NBIX ) to Overweight, target set at 163 → 168.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 17 at 6:31 AM
Enter: $NBIX NOV 21 2025 $140 CALLS Buy in Price: $6.78 - $8.50 Take Profit: $14.24 Stop Bleeding: $5.97 ROI Potential: 110% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
Latest News on NBIX
Doozio
Doozio Oct. 25 at 2:48 PM
$NBIX so this week on eps da huckleberries go thru da $$$ because 🐒🍌🧠⏰♾️
0 · Reply
CDMO
CDMO Oct. 23 at 8:33 PM
$NBIX nice runup into earnings
0 · Reply
IN0V8
IN0V8 Oct. 23 at 7:48 PM
$NBIX Bought at $19
1 · Reply
stoxx0007
stoxx0007 Oct. 22 at 1:40 PM
$NBIX 💪
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 21 at 4:45 PM
Enter: $NBIX NOV 21 2025 $145 CALLS Buy in Price: $4.93 - $5.18 Take Profit: $10.01 Stop Bleeding: $4.34 ROI Potential: 103% Exit Within: 3 Weeks https://moneygroup.us/alerts
1 · Reply
notreload_ai
notreload_ai Oct. 21 at 1:09 PM
Citi has a Buy rating and $175 price target for $NBIX , believing its pipeline success overshadows INGREZZA's competitive concerns and maintains market share.
0 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 10:54 AM
Citigroup updates rating for Neurocrine Biosciences ( $NBIX ) to Buy, target set at 175.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 20 at 5:30 PM
Enter: $NBIX NOV 21 2025 $145 CALLS Buy in Price: $4.93 - $5.80 Take Profit: $7.15 Stop Bleeding: $4.34 ROI Potential: 45% Exit Within: 2 Weeks https://moneygroup.us/alerts
0 · Reply
JarvisFlow
JarvisFlow Oct. 20 at 3:41 PM
Morgan Stanley updates rating for Neurocrine Biosciences ( $NBIX ) to Overweight, target set at 163 → 168.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 17 at 6:31 AM
Enter: $NBIX NOV 21 2025 $140 CALLS Buy in Price: $6.78 - $8.50 Take Profit: $14.24 Stop Bleeding: $5.97 ROI Potential: 110% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
stoxx0007
stoxx0007 Oct. 16 at 11:43 AM
$NBIX = good place to be... Right here - Right Now! NBIX
0 · Reply
pinupinu
pinupinu Oct. 16 at 9:36 AM
$GWPH $IMMU $IXHL $NBIX $PCYC agree completely. The shorting rats will be smoked soon
0 · Reply
Zaidyboy
Zaidyboy Oct. 16 at 9:30 AM
0 · Reply
stockro1
stockro1 Oct. 16 at 9:27 AM
I can’t overstate how positive I am about $IXHL. For me, it’s simply a matter of time. If success means making money from this stock, I’ve already done that. Enough to be happy. But now, my conviction runs deeper than asking when this will pump. After taking the time to dig into patents, explore competitors, and truly understand what Incannex is building - the value of their drug, its unique benefits, and its potential to solve a real human problem - I see something rare. Potentially a unicorn in the making. Think $GWPH, $IMMU, $PCYC, $NBIX… The bears might call this “hopium” or try to slander it, but I don’t care. This will outgrow them. It baffles me why some people spend their energy being negative or betting against it. They might win a day, a week, even a month, but in the long run they’ll lose. Can’t wait to see Incannex flourish and to have been here early. 🫶
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 10 at 6:41 PM
Enter: $NBIX NOV 21 2025 $140 CALLS Buy in Price: $8.30 - $8.30 Take Profit: $15.27 Stop Bleeding: $7.30 ROI Potential: 84% Exit Within: 257 Minutes https://moneygroup.us/alerts
0 · Reply
JarvisFlow
JarvisFlow Oct. 9 at 5:35 PM
UBS has updated their rating for Neurocrine Biosciences ( $NBIX ) to Buy with a price target of 195.
0 · Reply
IN0V8
IN0V8 Oct. 8 at 1:47 PM
$NBIX Buy RBC raises target price to $156 from $149
0 · Reply
ZorTrades
ZorTrades Oct. 7 at 3:04 PM
With all these leveraged single-stock ETFs… who’s really going to trade the singles? GraniteShares just launched $ISRG and $NBIX leveraged plays — $ISUL and $NBIL. They can’t come out with an inverse quantum ETF quick enough. ⚡️ (ionz)
1 · Reply
TB2025
TB2025 Oct. 7 at 2:44 PM
$RVPH $NBIX in three years it would take for Neurocrine's current lead candidate, if this new trial design even works, they could already have this launched for schizophrenia indication and be submitted for Psoriasis. All before their candidate is even ready for submission. Puts $NBIX as the lead anti inflammatory Pharmaceutical Company! 🚀💎
0 · Reply
AlpacaD
AlpacaD Oct. 7 at 8:53 AM
$RVPH $NBIX NBIX are not going to partner with Reviva for one massive reason. Competition. NB1117568, their schizophrenia drug, is about to start P3 trials. They are not going to partner with a company that will likely be their competition in a couple of years time.
3 · Reply
TB2025
TB2025 Oct. 7 at 3:17 AM
$RVPH Okay, one more question after the Mike Sibley news at $NBIX . Why hire a top-tier GM/SVP with recent Dermatology experience from Sanofi to run a Neuropsych franchise? $RVPH 's Brilaroxazine secondary imdications trial is in Psoriasis! This perfectly sets Neurocrine up for a huge entry into the Neuropsych and Derm Inflammation space. Acquisition is coming. 🚀💎
0 · Reply
TB2025
TB2025 Oct. 7 at 2:51 AM
$RVPH Could $NBIX Neurocrine hired this new GM today to oversee a new business unit they are taking on with Reviva Pharma and Brilaroxazine???? Typically a new GM added before an acquisition is made....
1 · Reply